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Background: Both ginsenoside Re and B-complex vitamins are widely used as nutritional supplements.
They are often taken together so as to fully utilize their antifatigue and refreshing effects, respectively.
Whether actually a drugenutrient interaction exists between ginsenoside Re and B-complex vitamins is
still unknown. The objective of this study was to simultaneously investigate the effect of B-complex
vitamins on the antifatigue activity and bioavailability of ginsenoside Re after their oral administration.
The study results will provide valuable theoretical guidance for the combined utilization of ginseng and
B-complex vitamins.
Methods: Ginsenoside Re with or without B-complex vitamins was orally administered to mice to
evaluate its antifatigue effects and to rats to evaluate its bioavailability. The antifatigue activity was
evaluated by the weight-loaded swimming test and biochemical parameters, including hepatic glycogen,
plasma urea nitrogen, and blood lactic acid. The concentration of ginsenoside Re in plasma was deter-
mined by liquid chromatographyetandem mass spectrometry.
Results: No antifatigue effect of ginsenoside Re was noted when ginsenoside Re in combination with B-
complex vitamins was orally administered to mice. B-complex vitamins caused to a reduction in the
bioavailability of ginsenoside Re with the area under the concentrationetime curve from zero to inﬁnity
markedly decreasing from 11,830.85  2,366.47 h$ng/mL to 890.55  372.94 h$ng/mL.
Conclusion: The results suggested that there were pharmacokinetic and pharmacodynamic drugenu-
trient interactions between ginsenoside Re and B-complex vitamins. B-complex vitamins can signiﬁ-
cantly weaken the antifatigue effect and decrease the bioavailability of ginsenoside Re when
simultaneously administered orally.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ginseng is the root of Panax ginseng Meyer, which has been
used as a kind of herbal medicine in the Oriental countries for
thousands of years. In 2009, the International Codex Alimentarius
Commission in the 32nd session passed the international standards
for ginseng, which stipulated that cultivated ginseng can be used
in food, thereby allowing ginseng to be more widely used as a kind
of herbal medicine and functional food. The main bioactive con-
stituent of ginseng is ginsenoside, which is usually extracted and
evaluated in biochemical analysis. So far, over 180 types ofonomic Animals and Plants, Chines
ht  2016, The Korean Society of G
d/4.0/).
t al., Effect of B-complex vita
Research (2016), http://dx.dginsenoside have been identiﬁed [1,2]. Ginsenoside Re is one of
the major constituents of ginsenosides. This exhibits many bio-
activities including antifatigue effects, antioxidant effects, protec-
tion of endothelial cells, and attenuation of diabetes-associated
cognitive deﬁcits [3e5].
B vitamins are water soluble. Adequate levels of vitamin B are
essential for the optimal performance and metabolic activity of a
host and several studies have also conﬁrmed that they can improve
cognitive performance and mood [6e9]. However, they cannot be
synthesized by the human body, and thus, daily intakes are
necessary. B vitamins mainly include vitamin B1, vitamin B2,e Academy of Agricultural Sciences, 4899 Juye Street, Changchun 130112, PR China.
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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vitamin B12. B vitamins as a group are essential for the normal
functioning of all living cells. If there is a reduction in the levels of
one of the B vitamins, the entiremetabolic process rapidly comes to
a standstill. To achieve best results, all kinds of B vitamins should be
taken together [10]. Therefore, B-complex vitamins are often rec-
ommended as nutritional supplements.
Nowadays, both ginsenoside Re and B-complex vitamins are
widely used as nutritional supplements. They are often taken
together so as to fully utilize their antifatigue and refreshing effects,
respectively. However, drug and nutrient as exogenous substances
are absorbed into the body and share several common sites of
transport, absorption, distribution, metabolism, and elimination,
each of which may lead to the drugenutrient interaction. Whether
actually a drugenutrient interaction exists between ginsenoside Re
and B-complex vitamins is still unknown. Drugenutrient in-
teractions draw less attention than drugedrug interactions [11e13].
The objective of this study was to simultaneously investigate the
effect of B-complex vitamins on the antifatigue activity and
bioavailability of ginsenoside Re after their oral administration. The
study results will provide valuable theoretical guidance for the
combined utilization of ginseng and B-complex vitamins.2. Materials and methods
2.1. Chemicals and reagents
Ginsenoside Re ( 98.0% purity) was purchased from School of
Chemistry, Jilin University (Changchun, China). Digoxin [internal
standard (IS)] with purity of 98.0% or more was purchased from
Pure Chemical Standard Co., Ltd. (Chengdu, China). Vitamin B1 (
99%), vitamin B2 ( 98%), vitamin B3 ( 99%), vitamin B5 ( 99%),
vitamin B6 ( 99%), vitamin B7 ( 97%), vitamin B9 ( 97%), and
vitamin B12 ( 98%) were purchased from Shanghai Yuanye Bio-
Technology Co., Ltd. (Shanghai, China). Liver glycogen assay kits,
urea assay kits, and lactic acid (LA) assay kits were purchased from
Nanjing Jiancheng Bioengineering Institute (Nanjing, China).
Ammonium hydroxide (HPLC grade) was purchased from Beijing
Chemical Works (Beijing, China).
Solid-phase extraction (SPE) columns (Oasis HLB 3 cm3/60 mg)
were purchased from Waters (Milford, MA, USA). Methanol and
acetonitrile (both HPLC grade) were purchased from Fisher Scien-
tiﬁc (NJ, USA). Milli-Q (Millipore) water was used in all experi-
ments. All other chemicals were of HPLC or analytical grade.2.2. Animals
ICR strain male mice (weight 17e21 g) for the antifatigue
experiment were purchased from Yisi Laboratory Animal Tech-
nology Co., Ltd. [Qualiﬁed No. SCXK (Ji)-2011-0004, Changchun,
China] and male Sprague-Dawley rats (weight 230e260 g) for the
bioavailability experiment were purchased from Changsheng Bio-
Technology Co., Ltd. [Qualiﬁed No. SCXK (Liao)-2010-0001, Dalian,
China]. Animals were housed under standard conditions in an an-
imal house with free access to food and water, with a 12:12-h
lightedark cycle at a consistent temperature (22  2C) and hu-
midity (50%  10%). All experiments were designed in accordance
with the Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health and approved by the Committee of the
Institute of Special Economic Animals and Plants, Chinese Academy
of Agricultural Science.Please cite this article in press as: Chen YB, et al., Effect of B-complex vita
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2.3.1. Grouping and treatment
After a 7-d acclimatization to the laboratory conditions, a total of
160 male ICR mice were randomly divided into the following four
groups (n ¼ 40 per group): control group (normal saline); Re group
(5 mg/kg ginsenoside Re); B-complex vitamins group (vitamin B1
2.25mg/kg, vitaminB2 2.25mg/kg, vitaminB37.50mg/kg, vitamin B5
3.45mg/kg, vitaminB61.50mg/kg, vitaminB722.50mg/kg, vitaminB9
60.00 mg/kg, and vitamin B12 1.50 mg/kg [6e9]); and mixture group,
which received both ginsenoside Re and B-complex vitamins. The
administration dose, however, in themixture groupwas the same as
that used in the aforementioned three groups. Eachmousewasorally
administeredwith thedrug for 30consecutivedays. Thehealth status
of themicewasobservedeachdayandallmicewereweighed every 2
d. According to the Technical Standards for Testing and Assessment of
Health Food (2003 edition), the weight-loaded swimming time, he-
patic glycogen level, plasma urea nitrogen level, and blood LA level
were tested to estimate the antifatigue effect [14].
2.3.2. Loaded swimming test
In brief, the test involved the following steps: 30 min after the
last intragastric administration, a lead sheath, weighing 5% of the
body weight of the mouse, was tied to the root of the mouse tail.
Four tempered glass pools (50 40 40 cm) were ﬁlled with water
to a depth of 30 cm. The mice (10/group) were dropped into the
water. The swimming time (time from dropping into the water to
sinking underwater for over 10 s) was recorded. The water tem-
perature was 25  1C.
2.3.3. Determination of hepatic glycogen
In brief, determination of hepatic glycogen levels involved the
following steps: 30 min after the last intragastric administration,
the mice (10/group) were killed by cervical vertebral dislocation
and their liver tissues were extracted for further analysis. It is well-
known that glycogen in the liver tissues is unstable and loses ac-
tivity easily in vivo; thus, 100 mg liver tissue from each mouse was
weighed, cleaned using normal saline, dried with ﬁlter paper, and
then diluted in lye immediately. To estimate the quantity of
glycogen, the anthrone colorimetric method was adapted.
2.3.4. Determination of plasma urea nitrogen
In brief, determination of plasma urea nitrogen involved the
following steps: 30 min after the last intragastric administration,
the mice (10/group) were forced to swim in pools ﬁlled with water
maintained at 30  1C for 90 min without weight loading. After a
60-min resting period, blood was sampled from eyes and collected
in tubes containing heparin. Plasma samples were collected by
centrifugation for 10 min at 3,800 rpm, and concentrations of
plasma urea nitrogen were analyzed using urea assay kits.
2.3.5. Determination of blood LA
In brief, determination of blood LA involved the following steps:
30 min after the last intragastric administration, 20 mL of blood was
drawn from the mice (10/group) with a syringe needle using the
retro-orbital bleeding method. The mice were then forced to swim
for 10 min without weight loading, and blood was drawn imme-
diately after and 20 min after swimming. The LA levels were
measured using LA assay kits.
2.4. Bioavailability study
2.4.1. Experimental protocols and blood sampling
After a 7-d acclimatization to the laboratory conditions, the rats
were allowed to fast for 12 h with free access to water prior tomins on the antifatigue activity and bioavailability of ginsenoside Re
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groups (n ¼ 5 per subgroup) randomly, namely, the ginsenoside Re
group and themixture group. The ginsenoside Re group received an
oral dose of 200 mg/kg ginsenoside Re, whereas the mixture group
received an oral dose of 200 mg/kg ginsenoside Re and B-complex
vitamins (vitamin B1 1.5 mg/kg, vitamin B2 1.5 mg/kg, vitamin B3
5 mg/kg, vitamin B5 2.3 mg/kg, vitamin B6 1 mg/kg, vitamin B7
15 mg/kg, vitamin B9 40 mg/kg, and vitamin B12 1 mg/kg [6e9]).
Aliquots of 0.2-mL blood samples were collected at pre-
determined time points (0 h, 0.083 h, 0.25 h, 0.5 h, 1.0 h, 1.5 h, 2.0 h,
3.0 h, 5.0 h, 8.0 h, 10.0 h, 12.0 h, 24.0 h, and 48.0 h) via the caudal
vein after the administration of respective doses, and the samples
were added into tubes containing heparin. Subsequently, plasma
samples were prepared by centrifugation for 10 min at 3,800 rpm
and stored at 80C for further analysis.
2.4.2. Blood sample preparation
An aliquot of 50-mL plasma samples was removed from
the 80C storage and thawed under ambient temperature. Pre-
conditioning of the SPE column was performed by washing the
column with 3.0 mL methanol and 3.0 mL deionized water suc-
cessively. Plasma sample was spiked with 10 mL of an IS solution
(8 mg/mL digoxin dissolved in water) and then loaded onto a pre-
conditioned SPE column after diluting tenfold with 4% phosphoric
acid solution. The column was then washed with 1.0 mL of water
and 1.0 mL of methanol successively. The methanol eluent was
ﬁnally dried under a ﬂow of nitrogen at 37C and dissolved in
100 mL of water:methanol (50:50, v/v) for liquid chromatographye
tandem mass spectrometry (LCeMS/MS) analysis.
2.4.3. Liquid chromatographyetandem mass spectrometry analysis
A 5-mL aliquot of the prepared sample solution was used for the
LCeMS/MS analysis. The LCeMS/MS analysis was performed on
UPLC/XEVO TQ with electrospray ionization source (Waters). The
separation was achieved using a BEH C18 column (2.1  50 mm,
1.7 mm, Waters) with a mobile phase consisting of 0.01% (w/v)
ammonium hydroxideeacetonitrile solution as Solvent A and 0.01%
(w/v) ammonium hydroxide solution as Solvent B at a ﬂow rate of
0.5 mL/min. A gradient elution system was used as follows: 0e
1.0 min, 28e35% A; 1.0e1.5 min, 35e75% A; 1.5e2.5 min, 75% A;
2.5e3.0 min, 75e28% A; 3.0e4.0 min, 28% A. The column temper-
ature was kept constant at 35C. Mass spectrum analysis was car-
ried out using negative multiple reaction monitoring (MRM) mode.
The precursoreproduct ion pairs, fragmentor voltage (Frag. V in
volts), and collision energy (CE in volts) for the analytes were as
follows: m/z 945.7735 > 637.6352 for the quantitative ion pair of
ginsenoside Re (Frag. 72 V, CE 36 V), m/z 945.7735 > 475.5107 for
the qualitative ion pair of ginsenoside Re (Frag. 72 V, CE 44 V)
(Fig. 1); m/z 779.6530 > 649.5557 for the quantitative ion pair of ISFig. 1. Multiple reaction monitoring (MRM) chromatograms. (A) MRM chromatogram of gin
mass spectrum of ginsenoside Re in the plasma sample: m/z 945.7735> 637.6352 for the qua
current.
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ion pair of IS (Frag. 66 V, CE 44 V). The detection parameters were
optimized as follows: nebulizer pressure, 2.8 kV; source tempera-
ture, 150C; drying gas temperature, 450C; drying gas ﬂow,
1,000 L/h; nebulizer gas ﬂow, 50 L/h; and collision gas ﬂow,
0.16 mL/min.
2.5. Statistical analysis
All values were presented as the mean  standard deviation.
Pharmacokinetic parameters were estimated by the non-
compartmental model using WinNonlin 6.3 program package
(Pharsight Corporation, Mountain View, CA, USA). The parameters
include area under the concentrationetime curve from zero to the
last sampling time or inﬁnity (AUC 0et or AUC 0eN), maximum
observed concentration (Cmax), and maximum observed time
(Tmax). The AUC 0etwas calculated using the linear trapezoidal with
linear interpolation method and the AUC 0eN was extrapolated by
the AUC 0et, while Cmax and Tmax were read directly from individual
plasma concentrationetime data.
All statistical procedures were performed using SAS version 9.2.
First, the data were analyzed by homogeneity test for variance. If
the data exhibited homoscedasticity, the signiﬁcance of the mean
difference was determined by one-way analysis of variance
(ANOVA), followed by a least signiﬁcant difference (LSD) t test for
multigroup comparisons if the ANOVA manifested a signiﬁcant
difference. Otherwise, it was determined by the KruskaleWallis
test. All p values less than 0.05 were considered to indicate a sta-
tistically signiﬁcant difference; p less than 0.01 was considered
highly signiﬁcant difference.
3. Results
3.1. Effect of B-complex vitamins on the antifatigue activity of
ginsenoside Re
3.1.1. Effects on body weight change
The one-way ANOVA results indicated that there were no sig-
niﬁcant differences in the body weight of mice among the control,
Re, B-complex vitamins, and mixture groups during the initial and
terminal stages (p > 0.05; Table 1).
3.1.2. Effects on weight-loaded swimming test, levels of hepatic
glycogen, and levels of plasma urea nitrogen
According to the one-way ANOVA and LSD t test, the weight-
loaded swimming time and the hepatic glycogen and plasma urea
nitrogen levels of mice in the ginsenoside Re group showed a highly
signiﬁcant difference compared with those in the control group
(p < 0.01); however, there were no signiﬁcant differences in thesesenoside Re in the plasma sample after oral administration of ginsenoside Re. (B) MRM
ntitative ion pair and m/z 945.7735 > 475.5107 for the qualitative ion pair. TIC, total ion
mins on the antifatigue activity and bioavailability of ginsenoside Re
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Table 1
Effects of ginsenoside Re and B-complex vitamins on body weights in mice
Group Body weight (g)
Initial Terminal Increased
Control 20.79  2.36 33.50  3.46 12.71  3.31
Ginsenoside Re 20.55  2.24 33.23  2.35 12.69  2.89
B-complex vitamins 20.71  2.42 34.07  3.41 13.35  3.09
Mixture 21.08  2.17 33.67  2.82 12.59  3.26
Data are presented as mean  standard deviation.
J Ginseng Res 2016;-:1e64three indexes among the control, B-complex vitamins, and mixture
groups (Table 2).
3.1.3. Effects on blood LA level
According to the one-way ANOVA and LSD t test, compared with
the control group, only the ginsenoside Re-administrated group
demonstrated variations in the levels of blood LA (p < 0.05);
however, there were no signiﬁcant differences in the variance of
blood LA level among the control, B-complex vitamins, andmixture
groups (Table 3).3.2. Pharmacokinetic proﬁles
After oral administration of ginsenoside Re (200 mg/kg) and
ginsenosideRe (200mg/kg) in combinationwithB-complex vitamins
to rats, thepharmacokineticproﬁleswereobtainedandanalyzed. The
results showed that B-complex vitamins signiﬁcantly reduced the
bioavailability of ginsenoside Re after oral administration. Compared
with the ginsenoside Re group, the mixture group had lower Cmax1
(p < 0.01) and Cmax2 (p < 0.01), but higher apparent total clearance/
bioavailability (p < 0.01). There were no signiﬁcant differences
betweenTmax1 (p>0.05), Tmax2 (p>0.05), and t1/2 (half-life) (p>0.05)
of ginsenoside Re. Meanwhile, the AUC 0et and AUC 0eN ofTable 2
Effects of ginsenoside Re and B-complex vitamins on the loaded swimming time,
hepatic glycogen, and plasma urea nitrogen levels in mice
Group Loaded swimming
time (min)
Hepatic glycogen
(mg/g)
Plasma urea nitrogen
(mmol/L)
Control 5.34  1.14 12.90  3.17 9.17  1.27
Ginsenoside Re 9.67  2.36 ** 18.93  3.08 ** 7.38  0.64 **
B-complex
vitamins
5.02  0.82 14.39  3.26 9.24  2.55
Mixture 5.94  1.10 11.00  1.66 8.43  1.15
Data are presented as mean  standard deviation.
** p < 0.01, compared with the control group.
Table 3
Effects of ginsenoside Re and B-complex vitamins on the variance of blood LA level
in mice
Group Blood LA level (mmol/L)
Before
swimming
0 min after
swimming
20 min after
swimming
Variance of
blood LA 1)
Control 2.61  1.47 3.09  0.71 2.55  1.14 78.74  23.93
Ginsenoside Re 2.37  1.63 2.73  0.92 1.09  0.35 * 57.43  9.79 *
B-complex vitamins 2.36  0.57 2.95  0.41 2.89  1.23 72.53  11.48
Mixture 2.55  1.65 3.39  1.14 2.17  0.67 73.08  9.64
Data are presented as mean  standard deviation.
* p < 0.05, compared with the control group.
LA, lactic acid.
1) Variance of blood lactic acid¼ 5 (lactic acid level before swimmingþ 3 lactic
acid level 0 min after swimming þ 2  lactic acid level 20 min after swimming).
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rats than those in rats in the mixture group, respectively (Fig. 2;
Table 4).
3.3. Validation of the LCeMS/MS assay
The UPLC/XEVO TQ operated in the MRM mode (for LCeMS/MS
assay) was suitable for the quantitative analysis of ginsenoside Re
in rat plasma collected at different time points. Calibration stan-
dards were prepared by spiking working solutions into 50 mL of rat
blank plasma. Ginsenoside Re presented a good linearity with the
correlation coefﬁcient (R2) being higher than 0.99 over the ranges
of 1.0e1,000.0 ng/mL. The lower limit of quantitation and lower
limits of detection of these analytes using the rat blank plasma
were 0.8 ng/mL (S/N ¼ 10) and 0.2 ng/mL (S/N ¼ 3), respectively.
The speciﬁcity of the method was conﬁrmed by comparing MRM
chromatograms of Re and the IS for a blank rat plasma sample with
a spiked rat plasma sample. The analytes could be detected without
any signiﬁcant interference. The recoveries of ginsenoside Re
ranged from 91.9% to 98.9%, which were estimated using spiked
plasma at high, middle, and low concentrations. The precision of
the method was determined using the derivation of the peak areas
of quality-control (QC) plasma sample at six consecutive sampling
times. The relative standard deviation of ginsenoside Re was 1.0%.
The intraday precision of the method was 4.5%, which was deter-
mined using the derivation of the peak areas of QC plasma sample
at different sampling times on the same day. The interday precision
of the method was 7.1%, which was determined using the deriva-
tion of the peak areas of QC plasma sample on consecutive days.
4. Discussion
Ginsenoside Re has been demonstrated to exhibit antifatigue
effect and B-complex vitamins are common nutritional supple-
ments that provide refreshment. Ginsenoside Re and B-complex
vitamins are often taken simultaneously. Through the antifatigue
experiment in mice, we found that orally administrated Re showed
no signiﬁcant difference in the body weights of mice, but rather it
prolonged the weight-loaded swimming time (p < 0.01) compared
with mice in the control group. An analysis of biochemical pa-
rameters related to fatigue also demonstrated that the hepatic
glycogen level of mice in the Re group was signiﬁcantly increased
(p< 0.01), although the plasma urea nitrogen level and the variance
of LA after swimming were signiﬁcantly decreased compared with
those in the control group (p < 0.01 and p < 0.05, respectively).
These results indicated that ginsenoside Re exerts an antifatigue
effect. However, there were no signiﬁcant differences in the
weight-loaded swimming time, the hepatic glycogen level, the
plasma urea nitrogen level, and the variance of LA after swimming
among the mice in the control, B-complex vitamins, and mixture
groups, which indicated that B-complex vitamins do not have the
antifatigue effect; meanwhile, no antifatigue effect of ginsenoside
Re was noted when ginsenoside Re was orally administered to mice
in combination with B-complex vitamins.
Recent research has demonstrated that ginsenoside Re has a
poor bioavailability (only 0.24%) [15,16]. Drugedrug interactions
sometimes can inﬂuence the bioavailability of drugs, leading to
changes in pharmacodynamic proﬁles. We speculated that there
was a drugenutrient interaction between ginsenoside Re and B-
complex vitamins in vivo, resulting in the change of the antifatigue
effect of ginsenoside Re. Therefore, ginsenoside Re with or without
B-complex vitamins was orally administered to rats in the
bioavailability study. Our study results show that B-complex vita-
mins worsen the bioavailability of ginsenoside Re. Compared with
the ginsenoside Re group, themixture group hadmarkedly reducedmins on the antifatigue activity and bioavailability of ginsenoside Re
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Fig. 2. Mean plasma concentrationetime proﬁles of ginsenoside Re in rats. In the ginsenoside Re group, rats were orally administered ginsenoside Re (dose 200 mg/kg). In the
mixture group, rats were orally administered ginsenoside Re in combination with B-complex vitamins (dose 200 mg/kg).
Y.B. Chen et al / Interactions between Re and B-complex vitamins 5Cmax1 (p < 0.01) and Cmax2 (p < 0.01). Meanwhile, the AUC 0et and
AUC 0eN of ginsenoside Re in coadministration with B-vitamin
complex (mixture-treated rats) became one-fourteenth and one-
thirteenth of those noted in rats treated with only ginsenoside
Re, respectively. The results proved that there was a drugenutrient
interaction between ginsenoside Re and B-complex vitamins
in vivo, and this interaction is the most likely cause of reduction of
ginsenoside Re antifatigue effect.
As is the case with many other herbal extracts, ginsenoside Re
has poor absorption and bioavailability due to its poor membraneTable 4
Pharmacokinetic parameters of ginsenoside Re in rats after oral administration of
ginsenoside Re with and without B-complex vitamins
Group Ginsenoside Re Mixture
Tmax1 (min) 54  13 35  29
Cmax1 (ng/mL) 1,703.85  104.15 129.46  104.04 **
Tmax2 (min) 468  107 492  123
Cmax2 (ng/mL) 623.02  257.82 75.92  68.83 **
AUC 0et (h$ng/mL) 9,896.68  1,234.48 695.22  232.75 **
AUC 0eN (h$ng/mL) 11,830.85  2,366.47 890.55  372.94 **
t1/2 (min) 500.56  368.88 536.70  356.89
CL/F (L/min/kg) 0.32  0.044 3.91  0.46 **
Vd/F (L/kg) 250.73  159.70 3,019.93  2,166.78 **
MRT 0et (min) 664.57  79.16 849.52  341.70
MRT 0eN (min) 895.45  312.28 974.15  426.34
Data are presented as mean  standard deviation.
** p < 0.01, compared with the ginsenoside Re group.
AUC 0et, area under the concentrationetime curve from zero to the last sampling
time; AUC 0eN, area under the concentrationetime curve from zero to inﬁnity; CL/F,
apparent total clearance/bioavailability; MRT 0et, mean residence time from zero to
the last sampling time; MRT 0eN, mean residence time from zero to inﬁnity; Vd/F,
apparent volume of distribution/bioavailability.
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form self-micelles [20,21]. Oral administration of ginsenoside Re
mixed with B-complex vitamins signiﬁcantly reduced the initial
absorption of Re compared with administration of ginsenoside Re
alone in terms of Cmax and AUC. The reduction might be due to the
affected absorption of ginsenoside Re in the gastrointestinal tract,
rather than due to the decreased clearance as there were no sig-
niﬁcant differences in the t1/2 of Re in plasma [22]. Ginsenoside Re
and B vitamins may form some new macromolecular compounds
with lower lipid solubility, thus leading to the poorer membrane
permeability of ginsenoside Re. By contrast, most of the drugedrug
interactions are caused by metabolizing enzymes and P-glycopro-
tein (P-gp) [23e25]. The levels of cytochrome P450 enzymes in the
intestines are less than those in the liver. Therefore, we speculated
that the change in enzyme activity that contributed to the in-
teractions between ginsenoside Re and B-complex vitamins is
limited. Ginsenosides are a good substrate for P-gp [26,27], and it is
possible that B-complex vitamins could have enhanced the
expression levels of P-gp in intestines, which led to the poorer
absorption of ginsenoside Re. Some studies have suggested that the
transport mechanism of ginsenosides is passive diffusion [19,28];
by contrast, the main transport mechanism of B vitamins is active
transport [29,30]. However, because both passive diffusion and
active transport require a speciﬁc carrier protein, it is possible that
B-complex vitamins might interfere in the role of carrier protein of
ginsenoside Re. Nevertheless, elucidating and conﬁrming this role
needs additional studies.
In conclusion, the results presented in this work suggest that
when ginsenoside Re was orally administered in combination with
B-complex vitamins, there was a signiﬁcant reduction in the
bioavailability of ginsenoside Re, which can weaken the antifatigue
effect of ginsenoside Re. The results suggested that there weremins on the antifatigue activity and bioavailability of ginsenoside Re
oi.org/10.1016/j.jgr.2016.03.006
J Ginseng Res 2016;-:1e66pharmacokinetic and pharmacodynamic drugenutrient in-
teractions between ginsenoside Re and B-complex vitamins. Thus,
it is better not to orally administer ginsenoside Re and B-complex
vitamins simultaneously.
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